Madrigal Posts First Profitable Quarter as Rezdiffra Sales Hit $431.3M
MDGL sits 20% above its 52-week low of $399 on elevated volume (1.8× avg).
Summary
Madrigal reported its first profitable quarter — $55.4 million of net income on $431.3 million of Rezdiffra sales, up 50% — and crossed $1.1 billion in year-to-date sales. It also announced a new Phase 3 cirrhosis trial, with the key MAESTRO-NASH OUTCOMES data expected late 2027.
Key Events · Earnings and Guidance · MDGL
-
First Profitable Quarter
Q3 2026 net income of $55.4 million, or $1.83 per diluted share, versus a net loss of $114.2 million ($4.01 per share) in the prior-year period.
-
Rezdiffra Sales Up 50%
Q3 net sales of $431.3 million versus $287.3 million a year ago; year-to-date net sales of $1.1 billion make it a blockbuster.
-
Patient Count Nearly Doubles
More than 55,850 patients on Rezdiffra as of Sept. 30, 2026, nearly double the 3Q25 level; U.S. F2-F3 addressable market on track to grow more than 30% by year-end 2026.
-
New Phase 3 Cirrhosis Trial
MAESTRO-CSPH will enroll more than 2,000 F4c patients, with initiation expected in the first half of 2027 subject to regulatory discussions; MAESTRO-NASH OUTCOMES data expected late 2027.
Analysis · MDGL · Life Sciences
Madrigal crossed from losses to profit: Q3 net income of $55.4 million ($1.83 diluted per share) against a $114.2 million loss a year ago, on Rezdiffra net sales of $431.3 million, up 50%. Year-to-date sales of $1.1 billion make Rezdiffra a blockbuster less than three years after launch, and 55,850 patients on therapy show demand still compounding. The company also laid out its next leg: a second Phase 3 outcomes trial (MAESTRO-CSPH) in compensated cirrhosis, with the existing MAESTRO-NASH OUTCOMES readout expected late 2027. With $961.8 million in cash and the P&L now self-funding, the dilution risk that hung over the story is materially reduced.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDGL was trading at $477.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $399.00 to $615.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.